Lexeo Therapeutics Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

451.42M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	654.00K	-1.00M	-60.53%
Dec 31, 2021	1.66M	1.14M	219.59%
Dec 31, 2020	518.48K	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	422.82B
Johnson & Johnson	90.63B
Merck & Co.	63.62B
AbbVie	58.33B
AstraZeneca	56.50B
Novartis AG	55.19B
Eli Lilly and Company	53.26B
Novo Nordisk	49.11B

Revenue Rankings

LXEO News

6 days ago - Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback - Seeking Alpha
6 days ago - Lexeo Therapeutics, Inc. - Special Call - Seeking Alpha
7 days ago - Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
2 months ago - Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
3 months ago - Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewsWire
4 months ago - Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics - GlobeNewsWire
5 months ago - Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases - GlobeNewsWire
5 months ago - Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire

More News